Over the past two decades, marked progress has been made in treating non-small cell lung cancer (NSCLC) patients with EGFR-, ALK-, ROS1- and KRASG12C-targeted inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.